newsfilter
← Latest News
GlobeNewswire·

Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn's and Colitis Congress

SAN DIEGO, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative